glycans
(3)
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
Nikolina Lauc
Nikolina Lauc is co-founder and CEO of GlycanAge, a UK-based longevity diagnostics company built on two decades of glycobiology research from her father's laboratory in Zagreb. A serial entrepreneur since 18, she runs a business that translates a blood-based glycan test into a biological age readout, and she has become one of the more visible operators pushing preventive-health testing into the consumer market.
InterVenn Biosciences
InterVenn Biosciences is a South San Francisco biotech building an AI-driven glycoproteomics platform that reads the sugar coatings on proteins to detect disease earlier. Its flagship blood test, GlycoKnow Ovarian, distinguishes ovarian cancer from benign pelvic masses with ~86% accuracy and went commercial in 2025. Founded in 2017 by Aldo Carrascoso with chemists Carolyn Bertozzi (Nobel Laureate) and Carlito Lebrilla, the company has raised roughly $244M, including a $201M Series C led by SoftBank in 2021.